# US 2022/0033776 A1 · Methods of making platelets comprising modified receptors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033776 A1
- Document ID: US20220033776A1
- Status: Published application
- Kind: A1
- Application number: 17/280,415
- Filed: 2019-10-01
- Published: 2022-02-03
- Earliest claimed: 2018-10-05
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Tara Deans
- Web page: https://patentgrep.com/patent/US20220033776A1

## CPC

- C12N 5/0644: {Platelets; Megakaryocytes}
- A61K 35/19: Platelets; Megacaryocytes
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 15/79: Vectors or expression systems specially adapted for eukaryotic hosts
- C12N 15/907: {in mammalian cells}
- C12N 2506/11: from blood or immune system cells
- C12N 2510/00: Genetically modified cells
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are methods of producing platelets comprising a modified receptor, therapeutic agents, peptides, and/or bioactive molecules. The cells produced by the methods disclosed herein can be used to treat, manage, prevent and diagnosis, for example, lysosomal storage diseases, diabetes and cancer. The cells produced by the methods disclosed herein can be engineered to comprise receptors capable of activating platelets to trigger the release of enzymes, biomolecules or therapeutic agents upon binding to specific drugs and/or binding to tissue specific peptides.

## Claims

### Claim 1

A nucleic acid construct comprising: a first genetic circuit comprising a tissue-specific promoter operatively linked to a sequence capable of encoding a modified receptor.

### Claim 2 (depends on 1)

The nucleic acid construct of claim 1, wherein the tissue-specific promoter is CXCL4, GPIIb, or PTPRC.

### Claim at position 3

-5. (canceled)

### Claim 6 (depends on 1)

The nucleic acid construct of claim 1, wherein the modified receptor is a modified G-protein coupled receptor (GPCR) or a modified protease-activated receptor (PAR).

### Claim 7 (depends on 6)

The nucleic acid construct of claim 6, wherein the modified GPCR is a Gq, a Gi, a Gs or a G12/G13 GPCR.

### Claim 8 (depends on 6)

The nucleic acid construct of claim 6, wherein the modified PAR is PAR1, PAR2, PAR3 or PAR4.

### Claim 9 (depends on 1)

The nucleic acid construct of claim 1, further comprising a second genetic circuit, wherein the second genetic circuit comprises one or more megakaryocyte differentiation genes.

### Claim 10 (depends on 9)

The nucleic acid construct of claim 9, wherein the one or more megakaryocyte differentiation genes are HoxB4, GATA1, c-MYC, BMI1, BCL-XL, PLK-1 or a combination thereof.

### Claim at position 9

-15. (canceled)

### Claim 16 (depends on 9)

The nucleic acid construct of claim 9, wherein the first genetic circuit or the second genetic circuit further comprises a gene of interest.

### Claim 17 (depends on 16)

The nucleic acid construct of claim 16, wherein the gene of interest is a therapeutic agent.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A pluripotent stem cell or a megakaryocyte comprising the nucleic acid construct of claim 1.

### Claim at position 15

-39. (canceled)

### Claim 40

An engineered platelet comprising a modified receptor, wherein the modified receptor is a modified G-protein coupled receptor (GPCR) or a modified protease-activated receptor (PAR).

### Claim 41

(canceled)

### Claim 42 (depends on 40)

The engineered platelet of claim 40, wherein the modified GPCR is a Gq, a Gi, a Gs or a G12/G13 GPCR.

### Claim 43 (depends on 40)

The engineered platelet of claim 40, wherein the modified PAR is PAR1, PAR2, PAR3 or PAR4.

### Claim 44 (depends on 40)

The engineered platelet of claim 40, further comprising a therapeutic agent.

### Claim 45 (depends on 1)

A method of producing a platelet or a population of platelets comprising a modified receptor, the method comprising:
a. providing pluripotent stem cells comprising any of the nucleic acid constructs of claim 1;
b. culturing the pluripotent stem cells in a media under conditions to permit the expansion of the pluripotent stem cells to megakaryocytes; and
c. differentiating the megakaryocytes into platelets;
wherein the platelets or the population of platelets comprise the modified receptor.

### Claim at position 22

-56. (canceled)

### Claim 57 (depends on 40)

A method of treating a human patient, the method comprising: a) administering one or more of the platelets of claim 40 to the human patient; and b) administering an exogenous agonist to the human patient; wherein the presence of the exogenous agonist activates the modified receptor.

### Claim 58

(canceled)

### Claim 59 (depends on 57)

The method of claim 57, wherein the human patient has cancer, diabetes, or lysosomal storage disease.

### Claim at position 26

-63. (canceled)

### Claim 64 (depends on 44, 57)

The method of claim 57, wherein the activation of the modified receptor induces the release of the therapeutic agent from the platelet of claim 44 or one or more endogenous biomolecules.

### Claim 65 (depends on 57)

The method of claim 57, wherein the one or more platelets or the population of platelets is administered via intravenous injection or transfusion.

### Claim 66 (depends on 57)

The method of claim 57, wherein the exogenous agonist is administered via intracranial, instraspinal, intramuscular, or intravenous injection or orally.

### Claim at position 30

-71. (canceled)
